[Hokuriku Pharmaceutical: Obtained Drug Registration Certificate for Bemetoprost Eye Drops] On September 20, Bekriku Pharmaceutical (300016.SZ) announced that the company had received the "Drug Registration Certificate" for Bemetoprost Eye Drops approved and issued by the State Food and Drug Administration. This drug is used to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension. It has been included in the National Medical Insurance Category B Catalog. Domestic sales in 2024 and 2025 will be 18.62 million yuan and 16.69 million yuan respectively. This approval is deemed to have passed the quality and efficacy consistency evaluation of generic drugs, which will further enrich the company's preparation product pipeline and realize product layout in the field of ophthalmology.